Application of shape-based and pharmacophore-based in silico screens for identification of Type II protein kinase inhibitors

The identification of new, potent and selective inhibitors of important protein kinase targets is a major goal of drug discovery. Here we analyze the crystal structures of 55 protein kinase complexes with Type II inhibitors and find they adopt a conserved twisted V-shape, with an angle of 121 ± 8° and twist of 78 ± 8°. The tightly conserved twist appears important in ensuring ligands curve around the protein backbone and towards the deep pocket. From this, we develop predictive pharmacophore- and shape-based screens to identify Type II inhibitors from a database which also contains Type I inhibitors as decoys. Both approaches exhibit a good level of discrimination for Type II molecules. The most effective pharmacophore model requires six features and three excluded volume regions. Shape-based screening using ROCS generally performs at least as well as pharmacophore approaches. There is only a moderate dependence of shape-based or pharmacophore-based screens on the underlying conformer generator (MOE, Macromodel, Omega and SPE), as well as on ligand linkage chemistry (amide and urea). Finally, we apply our approach to retrieval of Type II inhibitors from a modified version of the DUD database, containing over 104,000 compounds. We observe good enrichment, providing further evidence that the in silico screens developed here will constitute useful guides for identification of small molecule inhibitors targetting protein kinases in their inactive conformational state.

[1]  G. Müller,et al.  Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition , 2008, Expert opinion on drug discovery.

[2]  Eric J. Martin,et al.  Conformational Sampling of Bioactive Molecules: A Comparative Study , 2007, J. Chem. Inf. Model..

[3]  J. Irwin,et al.  Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.

[4]  S. B. Needleman,et al.  A general method applicable to the search for similarities in the amino acid sequence of two proteins. , 1970, Journal of molecular biology.

[5]  G. Scapin.  Structural biology in drug design: selective protein kinase inhibitors. , 2002, Drug discovery today.

[6]  G. Müller,et al.  Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition , 2008, Expert opinion on drug discovery.

[7]  L. Tong,et al.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.

[8]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[9]  Malcolm J. McGregor,et al.  A Pharmacophore Map of Small Molecule Protein Kinase Inhibitors , 2007, J. Chem. Inf. Model..

[10]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[11]  Richard Kendall,et al.  Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor. , 2007, Journal of medicinal chemistry.

[12]  Christopher W Murray,et al.  Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. , 2005, Journal of medicinal chemistry.

[13]  P. Gallant,et al.  N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR. , 2008, Bioorganic & medicinal chemistry letters.

[14]  Andreas Zell,et al.  Optimal assignment methods for ligand-based virtual screening , 2009, J. Cheminformatics.

[15]  J. A. Grant,et al.  A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape , 1996, J. Comput. Chem..

[16]  Taebo Sim,et al.  A general strategy for creating "inactive-conformation" abl inhibitors. , 2006, Chemistry & biology.

[17]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[18]  Ji-Xia Ren,et al.  Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2. , 2009, Journal of molecular graphics & modelling.

[19]  Michael Gribskov,et al.  Use of Receiver Operating Characteristic (ROC) Analysis to Evaluate Sequence Matching , 1996, Comput. Chem..

[20]  Wang Shen,et al.  Discovery of a potent and selective aurora kinase inhibitor. , 2008, Bioorganic & medicinal chemistry letters.

[21]  T. Halgren,et al.  Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules , 1996 .

[22]  T. Halgren.  Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions , 1996 .

[23]  Eric J. Martin,et al.  Conformational Analysis of Macrocycles: Finding What Common Search Methods Miss , 2009, J. Chem. Inf. Model..

[24]  T. Hunter,et al.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.

[25]  C. Grütter,et al.  Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. , 2009, Journal of medicinal chemistry.

[26]  T. Halgren.  Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[27]  Simona Distinto,et al.  How To Optimize Shape-Based Virtual Screening: Choosing the Right Query and Including Chemical Information , 2009, J. Chem. Inf. Model..

[28]  R. Abagyan,et al.  Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. , 2008, Journal of medicinal chemistry.

[29]  Dimitris K. Agrafiotis,et al.  Conformational Sampling with Stochastic Proximity Embedding and Self-Organizing Superimposition: Establishing Reasonable Parameters for Their Practical Use , 2009, J. Chem. Inf. Model..

[30]  Daniel Elbaum,et al.  Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. , 2007, Journal of medicinal chemistry.

[31]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[32]  T. Halgren.  MMFF VI. MMFF94s option for energy minimization studies , 1999, J. Comput. Chem..

[33]  D. Berger,et al.  Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[34]  Thomas A. Halgren,et al.  Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94 , 1996, J. Comput. Chem..

[35]  Thomas A. Halgren,et al.  Merck molecular force field. IV. conformational energies and geometries for MMFF94 , 1996 .

[36]  Yutaka Maeda,et al.  Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[37]  J. A. Grant,et al.  A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.

[38]  E. Casale,et al.  Through the "gatekeeper door": exploiting the active kinase conformation. , 2010, Journal of medicinal chemistry.

[39]  Thierry Langer,et al.  Fast and Efficient in Silico 3D Screening: Toward Maximum Computational Efficiency of Pharmacophore-Based and Shape-Based Approaches , 2007, J. Chem. Inf. Model..

[40]  John Kuriyan,et al.  Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. , 2009, Cancer research.

[41]  Gerhard Müller,et al.  Fragment-based lead generation: identification of seed fragments by a highly efficient fragment screening technology , 2009, J. Comput. Aided Mol. Des..

[42]  T. Clackson,et al.  AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.

[43]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[44]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[45]  Daniel Rauh,et al.  Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. , 2009, Journal of the American Chemical Society.

[46]  Leonard Buckbinder,et al.  Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design , 2009, Journal of Biological Chemistry.